Maxigen Biotech (Taiwan) Insiders
| 1783 Stock | TWD 44.60 1.15 2.65% |
Maxigen Biotech employs about 20 people. The company is managed by 4 executives with a total tenure of roughly 47 years, averaging almost 11.0 years of service per executive, having 5.0 employees per reported executive. Recap of Maxigen Biotech's management performance can provide insight into the venture performance.
| PoHung Lai Insider Deputy Mang |
| ChingTing Chen Insider GM Director |
Maxigen |
Maxigen Biotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0926 %, meaning that it generated $0.0926 on every $100 dollars invested by stockholders. Maxigen Biotech's management efficiency ratios could be used to measure how well Maxigen Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Maxigen Biotech Workforce Comparison
Maxigen Biotech is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is presently estimated at about 239. Maxigen Biotech holds roughly 20.0 in number of employees claiming about 8% of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.19 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16. Maxigen Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Maxigen Biotech Price Series Summation is a cross summation of Maxigen Biotech price series and its benchmark/peer.
Maxigen Biotech Notable Stakeholders
A Maxigen Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Maxigen Biotech often face trade-offs trying to please all of them. Maxigen Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Maxigen Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| PoHung Lai | Deputy Mang | Profile | |
| ChingTing Chen | GM Director | Profile | |
| WanHow You | Financial Officer | Profile | |
| Karen Lee | Sr Admin | Profile |
About Maxigen Biotech Management Performance
The success or failure of an entity such as Maxigen Biotech often depends on how effective the management is. Maxigen Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Maxigen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Maxigen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and cosmeceutical skincare products in Taiwan and internationally. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan, Taiwan. MAXIGEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.
Please note, the imprecision that can be found in Maxigen Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Maxigen Biotech. Check Maxigen Biotech's Beneish M Score to see the likelihood of Maxigen Biotech's management manipulating its earnings.
Maxigen Biotech Workforce Analysis
Traditionally, organizations such as Maxigen Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Maxigen Biotech within its industry.Maxigen Biotech Manpower Efficiency
Return on Maxigen Biotech Manpower
| Revenue Per Employee | 25.6M | |
| Revenue Per Executive | 128M | |
| Net Income Per Employee | 4.4M | |
| Net Income Per Executive | 21.9M | |
| Working Capital Per Employee | 28M | |
| Working Capital Per Executive | 140M |
Additional Tools for Maxigen Stock Analysis
When running Maxigen Biotech's price analysis, check to measure Maxigen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maxigen Biotech is operating at the current time. Most of Maxigen Biotech's value examination focuses on studying past and present price action to predict the probability of Maxigen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maxigen Biotech's price. Additionally, you may evaluate how the addition of Maxigen Biotech to your portfolios can decrease your overall portfolio volatility.